SCHEMBL6388384

SCHEMBL6388384

CC(=O)c1ccc(CCNC(=O)C(F)(F)F)cc1

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.53
SMN1; SMN2 Q16637 3/20 0.53
MAPT P10636 2/20 0.53
RAB9A P51151 2/20 0.53
NPC1 O15118 1/20 0.53
KMT2A Q03164 3/20 0.52
MEN1 O00255 1/20 0.52
MLYCD O95822 2/20 0.49
KDM4E B2RXH2 1/20 0.47
F13A1 P00488 1/20 0.47
HSD17B10 Q99714 1/20 0.46
ESRRG P62508 2/20 0.46
ESRRB O95718 1/20 0.46
LMNA P02545 1/20 0.44
EPHX2 P34913 1/20 0.44
NR1H4 Q96RI1 1/20 0.44
POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3196978 0.85 MLYCD (0.54) ALDH1A1SMN1; SMN2RAB9ANPC1KMT2A
SCHEMBL3005286 0.84 MGLL (0.56) ALDH1A1SMN1; SMN2MAPTMLYCDHSD17B10
SCHEMBL10887210 0.84 MLYCD (0.47) ALDH1A1SMN1; SMN2RAB9ANPC1KMT2A
SCHEMBL14141265 0.83 NPC1 (0.59) ALDH1A1SMN1; SMN2MAPTRAB9ANPC1
SCHEMBL3833704 0.83 MLYCD (0.46) ALDH1A1SMN1; SMN2RAB9ANPC1MLYCD
SCHEMBL4179064 0.81 HPGD (0.57) ALDH1A1SMN1; SMN2RAB9ANPC1KMT2A
SCHEMBL6433557 0.81 KDM4E (0.61) ALDH1A1SMN1; SMN2MAPTRAB9ANPC1
SCHEMBL8145783 0.81 GSK3B (0.50) ALDH1A1SMN1; SMN2KMT2AMEN1MLYCD
SCHEMBL6329536 0.81 KDM4E (0.70) ALDH1A1SMN1; SMN2MAPTRAB9ANPC1
SCHEMBL14100869 0.81 ESRRG (0.61) RAB9ANPC1ESRRGESRRBEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4596534-A1 NONCOVALENT SMALL-MOLECULE INHIBITORS OF THE KEAP1-NRF2 INTERACTION University of Copenhagen (DK) 2025-08-06 EP disclosed
US-20050014787-A1 5-amidino-2-hydroxybenzenesulfonamide derivatives medicinal compoistions containing the same medicinal use thereof and intermediates in the production thereof KISSEI PHARMACEUTICAL CO., LTD. (JP) 2005-01-20 US disclosed
EP-1443041-A1 5-AMIDINO-2-HYDROXYBENZENESULFONAMIDE DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE SAME, MEDICINAL USE THEREOF AND INTERMEDIATES IN THE PRODUCTION THEREOF Kissei Pharmaceutical Co., Ltd. (JP) 2004-08-04 EP disclosed
US-6057451-A AMINOTHIAZOLE DERIVATIVES BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2000-05-02 US disclosed
EP-0871619-A1 PHENYL THIAZOLE DERIVATIVES WITH ANTI HERPES VIRUS PROPERTIES BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 1998-10-21 EP disclosed
WO-1997024343-A1 PHENYL THIAZOLE DERIVATIVES WITH ANTI HERPES VIRUS PROPERTIES BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 1997-07-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014787-A1 5-amidino-2-hydroxybenzenesulfonamide derivatives medicinal compoistions containing the same medicinal use thereof and intermediates in the production thereof F2, HYPK, F10 ALDH1A1 3117/4885SMN1; SMN2 1472/4885MAPT 2292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.